Autopsy report · NCT01119742

Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis

“Insufficient number of baseline eligible patient”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year before it stopped.
• 428 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Sun Pharmaceutical Industries, Inc.

Sponsor type

Industry

Conditions

Interdigital Tinea Pedis

Interventions

Butenafine Hydrochloride 1%; Butenafine Hydrochloride 1% B; Butenafine Hydrochloride 1%; Vehicle A; Vehicle B

Participants

428

Trials that died the same way

• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (71% match in meaning)
• Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
  “Insufficient number of patient records met inclusion criteria” (69% match in meaning)
• African American Families Fighting Parental Cancer Together
  “Insufficient patients meet eligibility requirements.” (66% match in meaning)
• Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)
  “Lack of eligible patients” (66% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.